New drug combo aims to fight Hard-to-Treat prostate cancer

NCT ID NCT02123758

Ongoing Disease control Sponsor: Aragon Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All participants take the drugs by mouth daily for up to 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-56021927 (ARN-509) combined with abiraterone acetate and prednisone
What this could lead to: If successful, this could lead to a more effective treatment option for men with metastatic castration-resistant prostate cancer.
What could go wrong: This is an early phase 1 trial with only 57 participants, so results are preliminary. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

Study site

Los Angeles, California, United States
Study site

San Francisco, California, United States
Study site

Houston, Texas, United States
Study site

Vancouver, British Columbia, Canada
Study site

Montreal, Quebec, Canada
Study site

Rotterdam, Netherlands
Study site

Sutton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.